EQS-News: Biotest AG / Key word (s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for ...
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...
This includes revenues from technology disclosure and from development services for Grifols, S.A. Previously, an increase in the high single-digit percentage range had been expected. The return on ...
Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged14-Nov-2024 / 08:56 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No ...
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management ...
Grifols SA (GIFLF) reports a 12.4% revenue increase and significant EBITDA improvement, while navigating financial expenses and market challenges.
Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of ...
Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...
Africa seeks U.S. vaccine commitment. Grifols and Moderna report promising earnings. Disparities in food health assessed ...
Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...
MADRID (Reuters) -Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback